Listen: How cancer-killing cell therapies work, biotech’s endless downturn, & an FDA conundrum

Can rewired cells cure some patients’ cancer? Do biotech stocks ever go up? And why’s it taking so long to get kids vaccinated for Covid-19?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Immunologist Katy Rezvani of MD Anderson Cancer Center joins us to explain the massive potential of a new approach to treating wily tumors, one that repurposes human immune cells. We also discuss the latest news in the life sciences, including an interesting hire at Novartis, the pediatric Covid-19 vaccine saga, and another negative milestone for biotech.

For more on what we cover, here’s the latest on NK cells for cancer; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].